Gail Roboz

29PUBLICATIONS

183CO-AUTHORS

Gene and molecular therapyPredictive and prognostic markersMedical mycologyMedical molecular engineering of nucleic acids and proteinsMolecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (29)

Sort by Publication Date:

|Jun 02, 2026

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

|Feb 24, 2026

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos

|Dec 15, 2025

2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party.

Jacqueline Cloos, Peter J M Valk, Christian Thiede

|Nov 21, 2025

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos

|Sep 25, 2025

Ziftomenib in Relapsed or Refractory <i>NPM1</i>-Mutated AML.

Eunice S Wang, Pau Montesinos, James Foran

|Jul 16, 2025

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome.

Jorge E Cortes, Jay Yang, Gail J Roboz

Pageof 5

Frequent Collaborators

10 joint publications

Andrew H Wei

David Sallman

Pau Montesinos

Naval G Daver

Elizabeth Griffiths

Rami S Komrokji

Hartmut Döhner

Karen Yee

Christopher S Hourigan

4 joint publications

Roland B Walter

Frequent Collaborators

10 joint publications

Andrew H Wei

5 joint publications

David Sallman

5 joint publications

Pau Montesinos

5 joint publications

Naval G Daver